Related Experiment Videos
CQA 206-291 in Parkinson's disease.
1University of Nebraska Medical Center, Section of Neurology, Omaha 68198-2045.
Clinical Neuropharmacology
|April 1, 1991
Summary
CQA 206-291 showed promise for Parkinson's disease treatment, improving symptoms with mild side effects. However, laboratory toxicity concerns led to its discontinuation in clinical development.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Parkinson's disease is a progressive neurodegenerative disorder.
- Current treatments aim to manage motor symptoms by modulating dopaminergic pathways.
Purpose of the Study:
- To evaluate the efficacy and tolerability of CQA 206-291 in patients with moderate Parkinson's disease.
- To assess the safety profile of this novel mixed D1-D2 receptor agonist.
Main Methods:
- A double-blind, placebo-controlled trial was conducted.
- Participants with moderate Parkinson's disease received CQA 206-291 or a placebo.
Main Results:
- Significant improvements in Parkinson's disease symptoms were observed in the CQA 206-291 treatment groups compared to placebo.
- Adverse effects associated with CQA 206-291 were predominantly mild and transient.
Conclusions:
- CQA 206-291 demonstrated potential as an effective and well-tolerated treatment for Parkinson's disease.
- Despite promising efficacy, laboratory-based toxicity concerns resulted in the withdrawal of CQA 206-291 from further clinical development.